3[4]Chang TT,Robeft GG,Robert M,et al.A comparison Of Entecavir and Lamivudinefor HBeAg-positive chronic hepatitis B.N Eng1 J Med,2006,354(10):1001-1010.
二级参考文献8
1Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B.Expert Rev Anti Infect ther, 2004, 2:853-871.
2Dienstag JL. The value and limitation of long term nucleoside antiviral therapy in chronic hepatitis B. J Hepatol, 2005, 42: 158-162.
3Chang TT, Hadziyannis S, Ciancian J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine therapy. Hepatology, 2002, 36:suppl. Abst 550.
4Tassopoulos N, Hadziyannis S, Ciancian J, et al. Entecavir is superior in treating patients with chronic hepatitis B who have failed lamivudine therapy.Hepatology, 2004, 40: suppl. Abst 673.
5Sherman M, Yurdaydin C, Sollano J, et, al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg ( + )chronic hepatitis B: Results of phase Ⅲ study ETV-026. Hepatology, 2004,40: suppl. Abst 1152.
6Tenny DJ, Levine SM, Rose RE, et al, Clinical emergence of entecavir resistant hepatitis B virus requires additional substitution in virus already resistant to lamivudine. Antimicrob Agent Chemother, 2004, 48:3498-3507.
7Honkoop P, deMan RA. Entecavir: A potent new antiviral drug for hepatitis B. Expert Opin Invest Drug, 2003, 12:683-688.
